These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9824099)

  • 1. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.
    Paulli M; Berti E; Boveri E; Kindl S; Bonoldi E; Gambini C; Rosso R; Borroni G; Straccapansa V; Magrini U; DeCoteau JE; Krammer PH; Möller P; Kadin ME
    Hum Pathol; 1998 Nov; 29(11):1223-30. PubMed ID: 9824099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
    Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
    Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
    Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
    J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
    Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
    Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
    Sigel JE; Hsi ED
    Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
    Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
    Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression.
    Levi E; Wang Z; Petrogiannis-Haliotis T; Pfeifer WM; Kempf W; Drews R; Kadin ME
    J Invest Dermatol; 2000 Dec; 115(6):1034-40. PubMed ID: 11121138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
    Nevala H; Karenko L; Vakeva L; Ranki A
    Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30-Positive Lymphoproliferative Disorders.
    Nikolaenko L; Zain J; Rosen ST; Querfeld C
    Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases.
    Kikuchi A; Nishikawa T
    Arch Dermatol; 1997 Jul; 133(7):829-33. PubMed ID: 9236520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
    Plaza JA; Feldman AL; Magro C
    J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis.
    Gniadecki R; Rossen K
    Br J Dermatol; 2003 May; 148(5):885-91. PubMed ID: 12786817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
    Nguyen PL; Harris NL; Ritz J; Robertson MJ
    Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
    Liang X; Smoller BR; Golitz LE
    J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
    Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
    J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.
    Mori M; Manuelli C; Pimpinelli N; Mavilia C; Maggi E; Santucci M; Bianchi B; Cappugi P; Giannotti B; Kadin ME
    Blood; 1999 Nov; 94(9):3077-83. PubMed ID: 10556192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary cutaneous CD30+ lymphoproliferative disorders].
    Calzado-Villarreal L; Polo-Rodríguez I; Ortiz-Romero PL
    Actas Dermosifiliogr; 2010 Mar; 101(2):119-28. PubMed ID: 20223154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.